Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 4/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.35 |
| ▸ | RELA | Q04206 | 4/20 | 0.35 |
| ▸ | FOS | P01100 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | TKT | P29401 | 1/20 | 0.30 |
| ▸ | XPO1 | O14980 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18187558 | 0.79 | TKT (0.35) | MALT1PDE4BTKT | |
| SCHEMBL19302652 | 0.75 | SORT1 (0.35) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL21428809 | 0.74 | MEN1 (0.39) | KMT2A | |
| Ammonia Solution, Strong SCHEMBL17353626 | 0.74 | SORT1 (0.35) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL19302653 | 0.73 | TKT (0.38) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL29953076 | 0.73 | MEN1 (0.36) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL25368592 | 0.72 | TKT (0.37) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL20487344 | 0.72 | MALT1 (0.33) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL21241462 | 0.72 | TKT (0.31) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL3925140 | 0.72 | HTT (0.36) | JUNNFKB1NFKB2RELAFOS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110337440-B | Compounds useful for inhibition of ROR-gamma-t | 伊莱利利公司 | 2021-08-03 | — | — | CN | disclosed |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY | 2020-02-13 | — | — | US | disclosed |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY | 2020-02-13 | — | — | US | disclosed |
| WO-2018160550-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008336-B2 | Compounds useful for inhibiting RORγt | RORB, RORC, RORA | JUN 1386/4885NFKB1 608/4885NFKB2 430/4885 |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | RORC, RORB, RORA | JUN 1570/4885NFKB1 669/4885NFKB2 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.